Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 46 |
| Active Pipeline (Recruiting Now) | 19 (14) |
| Completed vs Stopped Early | 17 / 10 (21.7%) |
| Median Closed Actual Enrollment | 81 participants |
| Physical Hospital Site Disclosure | 97.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 4 (3 since 2018) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Neurocrine Biosciences Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.